Date | Title | Description | |
---|---|---|---|
24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
Date | Title | Description | |
---|---|---|---|
21 Oct 2021 | Liquidity and counterparty agreements | Download | |
07 Oct 2021 | Liquidity and counterparty agreements | Download | |
04 Oct 2021 | Liquidity and counterparty agreements | Download | |
01 Sep 2021 | On business and financial situation | ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine | Download |
28 Jul 2021 | On business and financial situation | The company releases the press release related to first half 2021 financial results | Download |
Pages
Date | Title | Description | |
---|---|---|---|
21 Feb 2012 | Información sobre resultados (2) | Download | |
21 Feb 2012 | Información sobre resultados | Download | |
21 Feb 2012 | Informe Anual de Gobierno Corporativo | Download | |
15 Feb 2012 | Cambios en política de inversión, áreas de negocio y líneas de productos | Download | |
22 Dec 2011 | Composición del Consejo de Administración | Download |